Cerba Research

Cellix is dedicated to providing our customers with easy-to-use benchtop instruments for cell analysis, cell sorting and customised solutions for microfluidics.

Cellix was spun-out from Trinity College Dublin in 2006 when we launched our VenaFlux and Microfluidic Solutions ranges. Over the years, we have expanded our product offerings supporting our customers in several therapeutic areas including thrombosis, oncology, atherosclerosis, inflammation, infectious diseases, biofilm culture, stem cell research, sickle cell disease, asthma, and allergies. Our Microfluidic Solutions include set-ups for droplet generation, organ-on-chip and VOC analysis.

More recently, Cellix's multi-disciplinary team of engineers and scientists have been developing our Inish Solutions range: microfluidic label-free impedance cell analysis and sorting. We want our customers to succeed so we are demystifying flow cytometry and bringing them simple, easy-to-use cell analysis and sorting for every lab, not just core facilities.

Taros Chemicals GmbH & Co. KG, an independent, privately owned contract research organization based in Dortmund, Germany, has been serving the chemistry needs of pharmaceutical, chemical and biotech companies since its inception in 1999. A forerunner in the early German biotech scene, Taros can claim more than 13,000 syntheses, research and process chemistry projects delivered to-date to an increasingly expanding and diverse base of global customers.

In its state-of-the-art facilities in Dortmund's prestigious BioMedizinZentrum (BMZ), the hub of top ranking biotech organizations, Taros'​ team of highly creative and skilled scientists, aided by its state-of-the-art laboratory facilities, are wholly committed to solving a wide range of customers'​ R&D problems in innovative drug discovery, medicinal chemistry and classical synthetic chemistry. Their collective knowledge and experience in industrial organic chemistry, span a period of over 160 years, and in active drug discovery, around 60 years, covering the full spectrum, from big pharma to biotechnology. Taros is active today in therapeutic areas which include oncology, respiratory, CNS, cardiovascular, inflammation, pain, metabolism and infectious diseases, in all small-molecule target classes.

Our company's mission is to enhance the quality of human lives by providing advanced and innovative chemistry-driven technologies to our customers R&D endeavors in the global marketplace. We strive hard to provide creative, holistic and cost-effective solutions with the highest level of quality, reliability and integrity. We continuously endorse loyalty and commitment in our employees, inspiring them to provide exceptional value to our customers'​ R&D processes, by anticipating hurdles before they arise, by foreseeing potential cost and lead time reductions, and most importantly, by facilitating their competitive and "early to market"​ advantage.

Cellomatics Biosciences Ltd. (www.cellomaticsbio.com) is a laboratory-based Contract Research Organisation (CRO) specialised in Oncology/Immuno-Oncology, Immunology/Inflammation and Respiratory therapeutic areas.

We provide bespoke pre-clinical/early discovery phase laboratory services to support academic groups, pharmaceutical and biotechnology companies in their R&D studies and biomarker research.

The Company
- Founded in 2015 and Privately owned
- Operating out of Biocity, Nottingham
- Experienced Management team with track record of delivering complex scientific projects and peer reviewed
international publications
- Completed over 40 successful scientific projects in collaboration with over 25 sponsors
- Links with leading UK Universities
- Fully serviced laboratory with Specialised personnel
- National and International partners

Our USP:
- Dynamic CRO offering specialist skills with over 30 years of combined experience
- Therapeutic area expertise
- Value for money
- Efficient time management, thanks to our streamlined structure
- Flexibility in operations to suit our client needs.
- Customised service and support focused on customer retention and satisfaction
- Logistics support

Our vision is 'Integrated scientific services; from experimental conception to project delivery'​.

Our mission is:
- To revolutionise drug discovery research by providing integrated, cost-effective laboratory services including assay design consultancy, logistics support, bespoke high quality assay development/validation and data analysis.
- To be a responsible and trusted laboratory-based CRO partner with Quality, Flexibility, Reliability and Customer support as our indispensable asset.

Celentyx is a human immune system focused R&D and service company specialising in immuno-oncology, inflammation and autoimmunity in vitro assays using healthy donor and patient tissues and cells.

Celentyx’s unique ImmuKnowlogy™ platform allows rapid analysis of drug action on human immune cells - from healthy donors or patients with defined clinical disease. Drawing on the World-leading expertise of Celentyx personnel, which along with our strategic relationships with the MRC Centre for Immune Regulation and the Centre for Translational Inflammation Research (at the Queen Elizabeth 'Super-hospital', Birmingham), enables the human immune system to be investigated at the highest levels of resolution.

Celentyx's ImmuKnowlogy™ services enable partners to quantify efficacy, elucidate the mechanism of action of an immunomodulatory drug, facilitate lead candidate prioritisation or identify potentially negative impact of a drug on the human immune system prior to first administration to man.

Celentyx's Novel Clinical Indication Profiling™, which applies the powerful Immuno-Profiling™ platform to reprofile (repurpose) drug candidates for diseases of the human immune system (e.g. inflammation, autoimmune disease, allergy, graft rejection, lymphoma, leukaemia), has created an increasing portfolio of valuable drug indications.

Synovo GmbH is a Tübingen based pharmaceutical discovery services company with a focus on inflammation and innate immunity providing services in:

Medicinal Chemistry
Pharmacology
Cell Engineering
Peptide Modification

Synovo's main pharmacology activities are based on assays and models for the selection of drug candidates with improved properties of Absorption, Disposition, Metabolism and Elimination (ADME or DMPK). Synovo establishes these parameters using human derived cells, proteins and systems wherever feasible to ensure the relevance of its data to use in man.

Synovo is engaged in projects in the fields of anti-inflammatory and immune suppressive drug optimization on behalf of clients from the pharmaceutical industry. Synovo is also working in partnership with public sector laboratories to improve its systems and extend its technologies to protein and nucleic acid drugs.

Synovo is self-sustaining through its service business and it has always run profitably. The core of the services offering are pharmacological studies which it conducts mainly for biotech and mid-size companies. In addition, support functions like formulation chemistry and analytics enable more complex development studies.

In parallel, Synovo uses its skills and facilities to conduct innovative research in collaboration with partners throughout the world. This has resulted in various drug candidates being developed for immune-oncology applications and more recently, inflammatory bowel disease and infection. Drug development is a long and costly process, so Synovo has also worked on projects which are easier to develop.

Based in Tübingen, home of one of the most prestigious and best known Universities in Germany, Synovo GmbH benefits from access to cutting edge technology, highly skilled staff and a magnificent location over looking the Swabian Alps.